
  
    
      
        
        It_PRP has_VBZ been_VBN more_JJR than_IN a_DT century_NN since_IN coccidioidomycosis_NNS was_VBD first_RB recognized_VBN as_IN a_DT
        serious_JJ disease_NN ,_, and_CC its_PRP$ etiology_NN and_CC epidemiology_NN have_VBP been_VBN well_RB documented_VBN ._. But_CC the_DT
        disease_NN remains_VBZ an_DT enigma_NN to_TO many_JJ ,_, and_CC it_PRP often_RB goes_VBZ undiagnosed_JJ ,_, even_RB in_IN endemic_JJ areas_NNS ._. As_IN
        management_NN of_IN this_DT chronic_JJ disease_NN remains_VBZ problematic_JJ ,_, new_JJ preventive_JJ or_CC therapeutic_JJ
        options_NNS are_VBP needed_VBN ._.
      
      
        Etiology_NNP and_CC Epidemiology_NNP
        Coccidioidomycosis_NNP is_VBZ a_DT fungal_NN disease_NN found_VBD only_RB in_IN the_DT Western_NNP Hemisphere_NNP ._. It_PRP is_VBZ
        caused_VBN by_IN two_CD nearly_RB identical_JJ species_NNS ,_, 
        Coccidioides_NNP immitis_NNS and_CC 
        C_NNP ._. posadasii_NN ,_, generically_RB referred_VBD to_TO as_IN the_DT “ Californian_NN” and_CC
        “ non-_NN Californian_NN” species_NNS respectively_RB [_NN 1_CD ]_NN ._. The_DT fungus_NN grows_VBZ in_IN a_DT mycelial_NN phase_NN (_( see_VB Box_NNP
        1_LS )_) in_IN the_DT soil_NN within_IN a_DT geographically_RB delineated_JJ area_NN of_IN the_DT United_NNP States_NNPS known_VBN as_IN the_DT
        Lower_JJR Sonoran_NNP Life_NNP Zone_NNP [_NN 2_CD ]_NN ._. This_DT semiarid_NN zone_NN encompasses_VBZ the_DT southern_JJ parts_NNS of_IN Texas_NNP ,_,
        Arizona_NNP ,_, New_NNP Mexico_NNP ,_, and_CC much_RB of_IN central_JJ and_CC southern_JJ California_NNP (_( Figure_NN 1_LS )_) ._.
        Endemic_NNP regions_NNS for_IN coccidioidomycosis_NNS have_VBP long_RB been_VBN identified_VBN in_IN semiarid_NN areas_NNS in_IN
        Mexico_NNP [_NN 3_CD ]_NN ,_, and_CC smaller_JJR endemic_JJ foci_NN have_VBP been_VBN described_VBN in_IN areas_NNS of_IN Central_NNP and_CC South_JJ
        America_NNP [_NN 4_CD ,_, 5_CD ]_NN ._. More_RBR recently_RB ,_, Brazil_NNP has_VBZ also_RB been_VBN found_VBN to_TO contain_VB endemic_JJ areas_NNS in_IN the_DT
        semiarid_NN northeastern_JJ states_NNS of_IN the_DT country_NN [_NN 6_CD ]_NN ._. The_DT climatic_JJ conditions_NNS and_CC flora_NNS of_IN these_DT
        states_NNS are_VBP similar_JJ to_TO those_DT in_IN endemic_JJ regions_NNS in_IN North_NNP ,_, Central_NNP ,_, and_CC South_NNP America_NNP ._. In_IN
        Latin_NNP America_NNP ,_, Mexico_NNP has_VBZ the_DT largest_JJS number_NN of_IN reported_VBD cases_NNS ,_, with_IN the_DT prevalence_NN of_IN
        infection_NN in_IN northern_JJ Mexico_NNP reported_VBD to_TO be_VB between_IN 10_CD %_NN –_NN 40_CD %_NN [_NN 7_CD ,_, 8_CD ]_NN ._. 
        C_NNP ._. posadasii_NN is_VBZ thought_VBN to_TO be_VB the_DT predominant_NN species_NNS in_IN Mexico_NNP
        [_NN 3_CD ]_NN ._.
        As_IN the_DT soil_NN dries_NNS or_CC nutrients_NNS become_VBP limiting_VBG ,_, the_DT fungus_NN reproduces_NNS asexually_RB by_IN
        disarticulating_VBG the_DT hyphae_NN into_IN small_JJ ,_, environmentally-resistant_JJ arthroconidia_NN
        (_( reproductive_JJ spores_NNS )_) (_( Figure_NN 2_LS )_) ._. These_DT are_VBP easily_RB aerosolized_JJ when_WRB the_DT soil_NN is_VBZ disturbed_VBN
        by_IN wind_NN or_CC human_JJ activities_NNS ._. Consequently_RB ,_, it_PRP is_VBZ the_DT inhalation_NN of_IN the_DT dust-borne_JJ
        arthroconidia_NN that_WDT leads_VBZ to_TO infection_NN by_IN this_DT pathogenic_JJ fungus_NN in_IN both_DT humans_NNS and_CC domestic_JJ
        or_CC wild_JJ mammals_NNS ._. Upon_IN inhalation_NN ,_, the_DT fungus_NN converts_VBZ to_TO a_DT unique_JJ life_NN cycle_NN of_IN alternating_VBG
        spherules_NNS and_CC progeny_NN endospores_NNS ,_, which_WDT comprises_VBZ the_DT parasitic_JJ phase_NN of_IN this_DT dimorphic_JJ
        fungus_NN (_( Figure_NN 2_LS )_) [_NN 9_CD ]_NN ._. Mycelial_NNP elements_NNS are_VBP only_RB occasionally_RB found_VBD in_IN diseased_JJ tissue_NN
        [_NN 10_CD ]_NN ._. Coccidioidomycosis_NNP is_VBZ not_RB contagious_JJ ;_: reports_NNS of_IN human-to-human_JJ spread_NN are_VBP extremely_RB
        rare_JJ ._. Hence_RB ,_, primary_JJ exposure_NN to_TO contaminated_JJ dust_NN is_VBZ the_DT sole_JJ risk_NN factor_NN for_IN the_DT
        acquisition_NN of_IN this_DT disease_NN ._.
        It_PRP is_VBZ estimated_VBN that_IN upwards_NNS of_IN 100_CD ,_, 000_CD primary_JJ coccidioidal_NN infections_NNS occur_VBP in_IN humans_NNS
        each_DT year_NN in_IN the_DT endemic_JJ areas_NNS of_IN the_DT United_NNP States_NNPS [_NN 11_CD ]_NN ._. In_IN recent_JJ years_NNS ,_, the_DT incidence_NN of_IN
        the_DT disease_NN has_VBZ increased_VBN in_IN California_NNP and_CC Arizona_NNP ,_, which_WDT may_MD be_VB partially_RB due_JJ to_TO the_DT
        rapid_JJ immigration_NN of_IN previously_RB unexposed_JJ persons_NNS from_IN states_NNS outside_IN the_DT endemic_JJ areas_NNS (_( in_IN
        other_JJ words_NNS ,_, the_DT pool_NN of_IN susceptible_JJ people_NNS has_VBZ increased_VBN )_) [_NN 12_CD ]_NN ._. In_IN the_DT United_NNP States_NNPS ,_,
        diagnosis_NN in_IN patients_NNS who_WP have_VBP symptoms_NNS is_VBZ established_VBN by_IN serodiagnosis_NNS in_IN conjunction_NN with_IN
        patient_NN history_NN ._. In_IN previous_JJ decades_NNS ,_, a_DT coccidioidal_NN skin_NN test_NN antigen_NN was_VBD a_DT useful_JJ adjunct_NN
        in_IN the_DT diagnosis_NN ,_, but_CC it_PRP became_VBD unavailable_JJ in_IN the_DT 1980_CD s_VBZ [_NN 13_CD ]_NN ._. The_DT incidence_NN of_IN primary_JJ
        pulmonary_JJ disease_NN outside_IN the_DT United_NNP States_NNPS is_VBZ not_RB established_VBN ;_: most_JJS reports_NNS are_VBP limited_VBN to_TO
        disseminated_VBN or_CC unusual_JJ cases_NNS [_NN 14_CD ]_NN ._. Diagnosis_NNP in_IN Latin_NNP America_NNP is_VBZ usually_RB based_VBN on_IN
        microbiologic_JJ findings_NNS ,_, as_IN serology_NN is_VBZ not_RB always_RB available_JJ [_NN 14_CD ]_NN ._.
      
      
        Clinical_NNP Features_NNPS
        In_IN their_PRP$ pioneering_JJ epidemiologic_JJ studies_NNS ,_, Smith_NNP and_CC colleagues_NNS found_VBD that_IN about_IN 60_CD %_NN of_IN
        exposures_NNS to_TO the_DT fungus_NN result_NN in_IN asymptomatic_JJ infection_NN [_NN 15_CD ]_NN ._. In_IN the_DT 40_CD %_NN of_IN patients_NNS who_WP
        have_VBP symptomatic_JJ disease_NN ,_, there_EX are_VBP protean_NN manifestations_NNS ._. These_DT range_NN from_IN a_DT primary_NN ,_, or_CC
        benign_JJ ,_, pulmonary_JJ infection_NN (_( commonly_RB known_VBN as_IN “ Valley_NNP Fever_NN” )_) to_TO a_DT progressive_JJ pulmonary_JJ
        or_CC extrapulmonary_JJ disease_NN involving_VBG the_DT skin_NN ,_, bones_NNS and_CC /_NN or_CC joints_NNS ,_, the_DT central_JJ nervous_JJ
        system_NN ,_, and_CC other_JJ organ_NN systems_NNS ._. Fortunately_RB ,_, most_JJS patients_NNS with_IN primary_JJ disease_NN recover_VB
        spontaneously_RB and_CC retain_VB lifelong_JJ immunity_NN to_TO exogenous_JJ reinfection_NN ._. Chronic_NNP and_CC
        disseminated_VBN disease_NN is_VBZ estimated_VBN to_TO occur_VB in_IN up_IN to_TO 5_CD %_NN of_IN infected_JJ individuals_NNS ,_, with_IN
        comparatively_RB more_JJR cases_NNS occurring_VBG in_IN older_JJR individuals_NNS and_CC in_IN males_NNS [_NN 12_CD ]_NN ._. The_DT most_RBS
        dangerous_JJ form_NN of_IN the_DT disease_NN is_VBZ meningeal_NN infection_NN ,_, which_WDT occurs_VBZ in_IN about_IN 0_CD ._. 15_CD %_NN –_NN 0_CD ._. 75_CD %_NN of_IN
        extrapulmonary_JJ coccidioidomycosis_NNS cases_NNS and_CC requires_VBZ treatment_NN for_IN life_NN [_NN 16_CD ]_NN ._.
        In_IN regions_NNS where_WRB tuberculosis_NNS rates_NNS are_VBP high_JJ ,_, the_DT two_CD diseases_NNS may_MD occur_VB together_RB ._.
        Tuberculosis_NNP and_CC coccidioidomycosis_NNS share_VBP common_JJ epidemiological_JJ ,_, clinical_JJ ,_, radiographic_JJ ,_,
        and_CC even_RB histopathological_JJ features_NNS ,_, making_VBG a_DT correct_JJ diagnosis_NN extremely_RB difficult_JJ in_IN
        cases_NNS where_WRB both_DT diseases_NNS coexist_NN ._. In_IN areas_NNS where_WRB both_DT diseases_NNS are_VBP endemic_JJ ,_, the_DT pertinent_JJ
        studies_NNS for_IN diagnosing_VBG both_DT conditions_NNS should_MD be_VB performed_VBN in_IN every_DT patient_NN with_IN compatible_JJ
        clinical_JJ features_NNS ._. The_DT diagnosis_NN of_IN one_CD of_IN them_PRP does_VBZ not_RB exclude_VB the_DT possible_JJ existence_NN of_IN
        the_DT other_JJ [_NN 17_CD ]_NN ._.
      
      
        Treatment_NNP
        Historically_NNP ,_, patients_NNS with_IN the_DT primary_JJ respiratory_JJ form_NN of_IN the_DT disease_NN were_VBD not_RB treated_VBN
        because_IN the_DT vast_JJ majority_NN recovered_VBD on_IN their_PRP$ own_JJ ._. Instead_RB ,_, such_JJ patients_NNS were_VBD given_VBN
        supportive_JJ care_NN and_CC were_VBD monitored_VBN ,_, often_RB with_IN radiographs_NNS ,_, until_IN the_DT disease_NN resolved_VBN ._. In_IN
        recent_JJ years_NNS ,_, however_RB ,_, an_DT increasing_VBG number_NN of_IN physicians_NNS are_VBP prescribing_VBG azole_NN antifungals_NNS
        in_IN cases_NNS of_IN primary_JJ disease_NN ,_, both_DT because_IN drugs_NNS like_IN fluconazole_NN have_VBP a_DT good_JJ safety_NN record_NN ,_,
        and_CC because_IN there_EX is_VBZ a_DT perception_NN that_DT treatment_NN may_MD prevent_VB progression_NN to_TO more_RBR serious_JJ
        forms_NNS of_IN the_DT disease_NN ._. This_DT latter_JJ presumption_NN ,_, however_RB ,_, is_VBZ not_RB supported_VBN by_IN controlled_VBN
        trial_NN data_NNS ._.
        All_DT cases_NNS of_IN chronic_JJ or_CC disseminated_VBN disease_NN call_NN for_IN antifungal_NN therapy_NN ,_, but_CC the_DT choice_NN
        of_IN drugs_NNS ,_, route_NN ,_, and_CC duration_NN of_IN therapy_NN is_VBZ highly_RB dependent_JJ on_IN the_DT form_NN of_IN the_DT disease_NN ,_,
        the_DT severity_NN and_CC site_NN (_( s_VBZ )_) of_IN infection_NN ,_, and_CC the_DT immune_JJ status_NN of_IN the_DT patient_NN ._. Galgiani_NNP and_CC
        colleagues_NNS have_VBP published_VBN clinical_JJ practice_NN guidelines_NNS on_IN the_DT choice_NN of_IN drug_NN and_CC duration_NN
        of_IN therapy_NN for_IN a_DT given_VBN form_NN of_IN the_DT disease_NN [_NN 18_CD ]_NN ._.
        There_EX are_VBP only_RB two_CD classes_NNS of_IN antifungal_NN therapy_NN routinely_RB used_VBD for_IN treatment_NN of_IN
        coccidioidomycosis_NNS ._. The_DT first_JJ class_NN is_VBZ the_DT polyenes_NNS ,_, with_IN amphotericin_NN B_NNP desoxycholate_NN and_CC
        the_DT newer_JJR lipid_NN formulations_NNS used_VBN for_IN the_DT more_RBR serious_JJ forms_NNS of_IN disease_NN ._. The_DT second_JJ class_NN
        is_VBZ the_DT azoles_NNS ,_, with_IN ketoconazole_NN ,_, fluconazole_NN ,_, itraconazole_NN ,_, and_CC the_DT newer_JJR analogue_NN
        voriconazole_NN as_IN available_JJ options_NNS ._. Voriconazole_NNP ,_, in_IN particular_JJ ,_, is_VBZ being_VBG used_VBN more_JJR and_CC more_RBR
        often_RB in_IN life-threatening_JJ mycoses_NNS ,_, and_CC was_VBD found_VBN to_TO be_VB better_JJR than_IN amphotericin_NN B_NNP in_IN the_DT
        primary_JJ therapy_NN of_IN invasive_JJ aspergillosis_NNS [_NN 19_CD ]_NN ._. According_VBG to_TO available_JJ reports_NNS ,_, treatment_NN
        in_IN Latin_NNP America_NNP usually_RB consists_VBZ of_IN one_CD of_IN the_DT azoles_NNS (_( fluconazole_NN or_CC itraconazole_NN )_) and_CC /_NN or_CC
        amphotericin_NN B_NNP desoxycholate_NN ;_: lipid_NN formulations_NNS are_VBP too_RB costly_JJ to_TO be_VB accessible_JJ [_NN 20_CD ]_NN ._.
        Treatment_NNP of_IN the_DT more_RBR serious_JJ or_CC aggressive_JJ forms_NNS of_IN the_DT disease_NN is_VBZ typically_RB of_IN long_JJ
        duration_NN and_CC often_RB results_VBZ in_IN less_JJR than_IN complete_JJ resolution_NN of_IN disease_NN ;_: relapse_NN is_VBZ common_JJ
        [_NN 21_CD ]_NN ._. Unfortunately_RB ,_, information_NN on_IN the_DT treatment_NN of_IN coccidioidomycosis_NNS is_VBZ limited_VBN ,_, due_JJ to_TO
        the_DT small_JJ numbers_NNS of_IN controlled_VBN trials_NNS performed_VBN for_IN what_WP is_VBZ perceived_VBN to_TO be_VB a_DT niche_NN
        market_NN ._. Clearly_RB ,_, newer_JJR ,_, more_RBR powerful_JJ drugs_NNS are_VBP needed_VBN ._.
        In_IN addition_NN to_TO drugs_NNS ,_, surgery_NN is_VBZ sometimes_RB indicated_VBN to_TO remove_VB focalized_JJ infections_NNS ,_,
        such_JJ as_IN pulmonary_JJ cavities_NNS ,_, or_CC to_TO debride_NN osseous_JJ forms_NNS of_IN the_DT disease_NN [_NN 22_CD ]_NN ._.
      
      
        Immunology_NNP and_CC the_DT Basis_NNP for_IN a_DT Vaccine_NNP
        Acquired_VBN resistance_NN to_TO coccidioidomycosis_NNS strongly_RB correlates_NNS with_IN the_DT development_NN of_IN a_DT
        delayed-type_JJ hypersensitivity_NN skin_NN test_NN response_NN to_TO coccidioidal_NN antigens_NNS [_NN 23_CD ]_NN and_CC the_DT
        production_NN of_IN T-_NNP helper-_NN 1_CD (_( Th_NNP 1_LS )_) -_: associated_VBN cytokines_NNS to_TO coccidioidal_NN antigens_NNS ,_, such_JJ as_IN
        interferon-gamma_JJ (_( IFN-γ_NNP )_) and_CC Interleukin-_NNP 2_CD (_( IL-_NNP 2_LS )_) [_NN 24_CD ]_NN ._. Humoral_NNP immunity_NN plays_VBZ no_DT known_VBN
        role_NN in_IN overcoming_VBG infection_NN ._.
        Although_IN all_DT humans_NNS are_VBP equally_RB susceptible_JJ to_TO initial_JJ infection_NN ,_, there_EX is_VBZ evidence_NN of_IN
        genetic_JJ predisposition_NN to_TO dissemination_NN ,_, independent_JJ of_IN socioeconomic_JJ or_CC environmental_JJ
        factors_NNS ,_, particularly_RB among_IN African-_NNP Americans_NNPS and_CC Filipinos_NNPS [_NN 25_CD ]_NN ._. Pregnancy_NNP is_VBZ also_RB a_DT risk_NN
        factor_NN ._.
        In_IN cases_NNS of_IN marked_JJ immunosuppression_NN ,_, either_CC in_IN advanced_VBD AIDS_NNP or_CC other_JJ forms_NNS of_IN
        depressed_VBN cellular_JJ immunity_NN ,_, the_DT management_NN of_IN coccidioidomycosis_NNS is_VBZ particularly_RB
        challenging_VBG and_CC requires_VBZ aggressive_JJ treatment_NN [_NN 26_CD ]_NN ._.
        As_IN previously_RB mentioned_VBN ,_, recovery_NN from_IN disease_NN confers_VBZ lifelong_JJ immunity_NN to_TO reinfection_NN ,_,
        and_CC is_VBZ a_DT rationale_NN for_IN the_DT development_NN and_CC implementation_NN of_IN a_DT vaccine_NN for_IN the_DT prevention_NN
        of_IN symptomatic_JJ or_CC serious_JJ forms_NNS of_IN the_DT disease_NN ._. The_DT combination_NN of_IN increasing_VBG incidence_NN of_IN
        disease_NN ,_, a_DT growing_VBG population_NN in_IN the_DT endemic_JJ area_NN ,_, and_CC the_DT lack_NN of_IN a_DT highly_RB effective_JJ drug_NN
        treatment_NN justifies_VBZ efforts_NNS to_TO prevent_VB (_( rather_RB than_IN treat_VB )_) this_DT disease_NN ._. To_TO that_DT end_NN ,_, a_DT
        university-based_JJ consortium_NN ,_, the_DT Valley_NNP Fever_NN Vaccine_NNP Project_NNP (_( www_NN ._. valleyfever_NN ._. com_NN )_) ,_, has_VBZ
        identified_VBN and_CC cloned_VBN immunogenic_JJ proteins_NNS that_WDT have_VBP proven_VBN effective_JJ in_IN the_DT prevention_NN of_IN
        deaths_NNS and_CC fungal_NN burdens_NNS in_IN mouse_NN models_NNS of_IN coccidioidomycosis_NNS ._. This_DT suggests_VBZ that_IN a_DT
        vaccine_NN for_IN use_NN in_IN humans_NNS could_MD be_VB created_VBN [_NN 27_CD ]_NN ._. A_DT candidate_NN vaccine_NN comprised_VBN of_IN a_DT fusion_NN
        protein_NN based_VBN on_IN two_CD antigens_NNS has_VBZ been_VBN selected_VBN and_CC is_VBZ currently_RB in_IN pharmaceutical_JJ
        development_NN under_IN the_DT sponsorship_NN of_IN this_DT project_NN ,_, with_IN the_DT goal_NN of_IN evaluating_VBG the_DT safety_NN
        and_CC immunogenicity_NN in_IN humans_NNS ._.
      
      
        Conclusion_NNP
        Although_IN the_DT vast_JJ majority_NN of_IN infected_JJ individuals_NNS emerge_VBP from_IN coccidioidomycosis_NNS
        without_IN complications_NNS ,_, an_DT unlucky_JJ minority_NN are_VBP faced_VBN with_IN a_DT debilitating_JJ disease_NN that_WDT lacks_VBZ
        adequate_JJ drug_NN options_NNS for_IN rapid_JJ and_CC completely_RB effective_JJ treatment_NN ._. In_IN the_DT absence_NN of_IN newer_JJR
        therapeutics_NNS ,_, discoveries_NNS that_WDT lead_VBP to_TO immunologic_JJ intervention_NN [_NN 28_CD ]_NN or_CC prevention_NN by_IN
        vaccines_NNS may_MD ultimately_RB bring_VB a_DT measure_NN of_IN relief_NN ._.
      
    
  
